EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC 4.0

Pharmacokinetic and Exposure–Response Modeling Support Body Surface Area‐Based Dosing of Farletuzumab Ecteribulin in Japanese Patients with Solid Tumors

Seiichi Hayato iD, Lora Hamuro, Toshio Shimizu, Kan Yonemori, Shin Nishio iD, Mayu Yunokawa, Tatsuya Yoshida, Makoto Nishio, Koji Matsumoto, Kazuhiro Takehara, Kosei Hasegawa, Toshiyuki Kozuki und 7 weitere

The Journal of Clinical Pharmacology · 2025

DOI: 10.1002/jcph.6187 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift The Journal of Clinical Pharmacology, 2025. Verfasst von Seiichi Hayato und 18 weiteren Autor:innen. Beteiligte Einrichtung: Eisai Co. Ltd., Tokyo, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Models, Biological, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The first‐in‐human, Phase 1 Study 101 showed antitumor activity and a tolerable safety profile of farletuzumab ecteribulin in Japanese patients with platinum‐resistant ovarian and non‐small cell lung cancer. A pharmacometric assessment evaluated farletuzumab ecteribulin pharmacokinetics and exposure–response (E‐R) relationships for efficacy and safety to support dose optimization. Patients received 0.3‐1.2 mg/kg of farletuzumab ecteribulin intravenously every 3 weeks. A pharmacokinetics (PK) model was developed and used for E‐R analyses. Efficacy was assessed via tumor response and safety via known treatment‐emergent adverse events (TEAEs) of farletuzumab ecteribulin, particularly pneumonitis/interstitial lung disease (ILD). Dosing scenarios were simulated to identify dosing that maximizes the probability of an objective response while minimizing the risk of ILD. The farletuzumab ecteribulin PK dataset included 1261 observations from 82 patients. The final model included an estimated population mean value for farletuzumab ecteribulin clearance of 0.0162 L/h. Body surface area (BSA) was a significant PK covariate and was included in the model. Body weight (BW) was associated with higher farletuzumab ecteribulin exposure. Using BW‐based dosing, farletuzumab ecteribulin AUC (area under the serum concentration–time curve) was higher in patients with tumor response or stable disease versus patients with progressive disease and higher in patients with ILD and other TEAEs. Dosing simulations showed that BSA‐based dosing (33 mg/m 2 ) yielded similar tumor responses to BW‐based dosing (0.9 mg/kg) and decreased ILD rates. This study showed that BW‐based dosing resulted in higher risks of ILD events for patients with a high BW versus low BW, whereas BSA‐based dosing is predicted to reduce this risk while maintaining clinical efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntineoplastic AgentsModels, BiologicalNeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedBody Surface AreaCarcinoma, Non-Small-Cell LungDose-Response Relationship, DrugJapanLung NeoplasmsOvarian NeoplasmsEast Asian People

Stichwörter der Autor:innen

antibody–drug conjugatedose optimizationexposure–response analysisovarian cancerpopulation pharmacokinetics

Substanzen

Antibodies, Monoclonal, HumanizedAntineoplastic Agents

Autor:innen und Institutionen

  • Eisai Co. Ltd., Tokyo, Japan.
  • Bristol Myers Squibb, Princeton, NJ, USA.
  • Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
  • Department of New Experimental Therapeutics and International Cancer New Drug Development Center, Kansai Medical University Hospital, Osaka, Japan.
  • Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Department of Obstetrics and Gynecology, Kurume University School of Medicine, Fukuoka, Japan.

ORCID-Profile: Seiichi Hayato, Shin Nishio

Zitieren

APA

Hayato, S., Hamuro, L., Shimizu, T., Yonemori, K., Nishio, S., Yunokawa, M., Yoshida, T., Nishio, M., Matsumoto, K., Takehara, K., Hasegawa, K., Kozuki, T., Hirashima, Y., Kato, H., Miura, T., Nomoto, M., Zhao, Y., Zhu, L., & Yasuda, S. (2025). Pharmacokinetic and Exposure–Response Modeling Support Body Surface Area‐Based Dosing of Farletuzumab Ecteribulin in Japanese Patients with Solid Tumors. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.6187

Vancouver

Hayato S, Hamuro L, Shimizu T, Yonemori K, Nishio S, Yunokawa M, et al. Pharmacokinetic and Exposure–Response Modeling Support Body Surface Area‐Based Dosing of Farletuzumab Ecteribulin in Japanese Patients with Solid Tumors. The Journal of Clinical Pharmacology. 2025. doi:10.1002/jcph.6187

BibTeX
@article{Hayato2025,
  author = {Hayato, Seiichi and Hamuro, Lora and Shimizu, Toshio and Yonemori, Kan and Nishio, Shin and Yunokawa, Mayu and Yoshida, Tatsuya and Nishio, Makoto and Matsumoto, Koji and Takehara, Kazuhiro and Hasegawa, Kosei and Kozuki, Toshiyuki and Hirashima, Yasuyuki and Kato, Hidenori and Miura, Takuma and Nomoto, Maiko and Zhao, Yue and Zhu, Li and Yasuda, Sanae},
  title = {Pharmacokinetic and Exposure–Response Modeling Support Body Surface Area‐Based Dosing of Farletuzumab Ecteribulin in Japanese Patients with Solid Tumors},
  journal = {The Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1002/jcph.6187}
}
Kostenlos starten →